Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Aug;7(5):813-28.
doi: 10.2217/epi.15.21. Epub 2015 Sep 14.

Base resolution methylome profiling: considerations in platform selection, data preprocessing and analysis

Affiliations
Review

Base resolution methylome profiling: considerations in platform selection, data preprocessing and analysis

Zhifu Sun et al. Epigenomics. 2015 Aug.

Abstract

Bisulfite treatment-based methylation microarray (mainly Illumina 450K Infinium array) and next-generation sequencing (reduced representation bisulfite sequencing, Agilent SureSelect Human Methyl-Seq, NimbleGen SeqCap Epi CpGiant or whole-genome bisulfite sequencing) are commonly used for base resolution DNA methylome research. Although multiple tools and methods have been developed and used for the data preprocessing and analysis, confusions remains for these platforms including how and whether the 450k array should be normalized; which platform should be used to better fit researchers' needs; and which statistical models would be more appropriate for differential methylation analysis. This review presents the commonly used platforms and compares the pros and cons of each in methylome profiling. We then discuss approaches to study design, data normalization, bias correction and model selection for differentially methylated individual CpGs and regions.

Keywords: DNA methylation; bisulfite sequencing; differential methylation; methylation 450K array; normalization; reduced representation bisulfite sequencing; study design.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure This work is partially supported by Division of Biomedical Statistics and Informatics Meritorious Award (to Z Sun), Mayo Clinic Center for Individualized Medicine and National Cancer Institute (NCI R01CA118444 to S Slager). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.

Figures

<b>Figure 1.</b>
Figure 1.. Reduced representation bisulfite sequencing mechanism and flow diagram.
(A) Original DNA with CCGG motif at both ends. In human cytosine methylation occurs at CpG site (marked with m) and non-CpG cytosine is generally not methylated. The arrows point to the MSP1 cut sites, which is methylation independent. (B) After MSP1 digestion, DNA fragments are generated with sticky ends. Fragments in right sizes (generally 40–250 bps) for sequencing are selected. (C) The end repair adds CG (in blue, generally not methylated) from media that are not part of human sequence and needs to be removed in the analysis step. (D) The bisulfite treatment converts unmethylated cytosine to uracil but the methylated cytosine remains as cytosine. (E) The PCR amplification step converts/interprets uracil (U) as thymine (T). The amplification is based upon the original top and bottom strands, which are no longer complementary and generate their respective offspring sequences. For single end sequencing, only OT and OB sequences are used, however, for pair end sequencing all four strands are generated. Analysis need to group them correctly. OB: Original bottom strand; OBC: Original bottom strand complementary; OT: Original top strand; OTC: Original top strand complementary.

References

    1. Azuara D, Rodriguez-Moranta F, de Oca J, et al. Novel methylation panel for the early detection of colorectal tumors in stool DNA. Clin. Colorectal Cancer. 2010;9(3):168–176. - PubMed
    1. Hong L, Ahuja N. DNA methylation biomarkers of stool and blood for early detection of colon cancer. Genet. Test. Mol. Biomarkers. 2013;17(5):401–406. - PubMed
    1. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N. Engl. J. Med. 2014;370(14):1287–1297. - PubMed
    1. Shiovitz S, Bertagnolli MM, Renfro LA, et al. CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage iii colon cancer. Gastroenterology. 2014;147(3):637–645. - PMC - PubMed
    1. Fleischhacker M, Dietrich D, Liebenberg V, Field JK, Schmidt B. The role of DNA methylation as biomarkers in the clinical management of lung cancer. Expert Rev. Respir. Med. 2013;7(4):363–383. - PubMed

Publication types